Scholars Central

Conference abstractPublished 2018

Biosimilars and market strategy

Authors: Hareesh Parandhaman

Win With Biosimilars, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Hareesh strongly believes that building a strategy for Biosimilars at the corporate level and taking it to a product level is an extremely complex exercise. Most companies spend little time/resources in planning this move thoroughly. They are either undecided or when they decide; they jump right into it and regret their decisions when the product is ready to be marketed. Remember, that the market is not static but extremely dynamic and therefore one's Business Strategy has to align itself (real time in-sync) with the market dynamics. It is also getting very crowded with several players chasing the Biosimilars dream and companies like Samsung etc who were never into Pharmaceuticals have joined the party.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Nephrology & Renal Diseases.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Nephrology & Renal Diseases
  • SubjectNephrology & Urology
  • BylineArticles whose byline prints “Hareesh Parandhaman”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels